drug affinity complex is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-05-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
6-Aminoquinolyl-N-hydroxysuccinimidyl carbamate (AQC) is a fluorogenic, amine labeling dye that is not fluorescent itself, but covalently reacts with secondary amines to form a fluorescently labeled product. It has a fluorescence excitation wavelength of 250 nm (UV-C), and emission wavelength of 395 nm (deep violet, near UV).
In October 2023, the US Food and Drug Administration (FDA) approved Vamorolone (Agamree) as a Treatment for Duchenne muscular dystrophy. Catalyst Pharmaceuticals holds the exclusive North American license and commercial rights. In March 2024, the FDA approved givinostat (Duvyzat), an oral medication, to be used in the treatment of Duchenne muscular dystrophy in people aged six years and older. Givinostat is the first nonsteroidal drug to receive FDA approval for the treatment of all genetic variants of Duchenne muscular dystrophy. Functioning as a histone deacetylase (histone deacetylase (HDAC) inhibitor, givinostat operates by targeting pathogenic processes within the body, ultimately leading to a reduction in inflammation and muscle loss associated with the disease.
==== 500–599 ==== Water Supply and Sewerage Services (Customer Service Standards) (Amendment) Regulations 1993 (S.I. 1993/500) Local Government Finance Act 1992 (Community Charge Benefits) Saving Order 1993 (S.I. 1993/502) Bovine Animals (Identification, Marking and Breeding Records) (Amendment) Order 1993 (S.I. 1993/503) Prisoner Escorts Rules 1993 (S.I. 1993/515) Prison (Amendment) Rules 1993 (S.I. 1993/516) Common Agricultural Policy (Wine) Regulations 1993 (S.I. 1993/517) Social Security Benefits (Miscellaneous Amendments) Regulations 1993 (S.I. 1993/518) Occupational and Personal Pension Schemes (Miscellaneous Amendments) Regulations 1993 (S.I. 1993/519) Local Authorities (Capital Finance) (Amendment) Regulations 1993 (S.I. 1993/520) National Health Service (General Medical and Pharmaceutical Services) (Scotland) Amendment Regulations 1993 (S.I. 1993/521) National Health Service (Charges for Drugs and Appliances) (Scotland) Amendment Regulations 1993 (S.I. 1993/522) National Health Service (Dental Services) (Miscellaneous Amendments) (Scotland) Regulations 1993 (S.I. 1993/523) National Health Service (Optical Charges and Payments) (Scotland) Amendment Regulations 1993 (S.I. 1993/524) Education (Fees and Awards) (Scotland) Amendment Regulations 1993 (S.I. 1993/525) Council Tax (Dwellings) (Scotland) Regulations 1993 (S.I. 1993/526) Council Tax (Transitional Reduction Scheme) (Scotland) Amendment (No.2) Regulations 1993 (S.I. 1993/527) Legal Aid in Contempt of Court Proceedings (Scotland) Amendment Regulations 1993 (S.I.
Sources: en.wikipedia.org
== Cellular function == As an important actin regulator, gelsolin plays a role in podosome formation (along with Arp3, cortactin, and Rho GTPases). Gelsolin also inhibits apoptosis by stabilizing the mitochondria. Prior to cell death, mitochondria normally lose membrane potential and become more permeable. Gelsolin can impede the release of cytochrome C, obstructing the signal amplification that would have led to apoptosis. Actin can be cross-linked into a gel by actin cross-linking proteins. Gelsolin can turn this gel into a sol, hence the name gelsolin.
When the EWS detects a new drug, the substance will be reported to EMCDDA along with any analytical data such as structures, analysts or components found pertaining to that particular drug. Then, an interconnected system is established to closely monitor the development of the substance. If harm is induced, an initial report is drafted to document the adverse effects of the drug.
== X == XAES – X-ray induced Auger electron spectroscopy XANES – XANES, synonymous with NEXAFS (near edge X-ray absorption fine structure) XAS – X-ray absorption spectroscopy X-CTR – X-ray crystal truncation rod scattering X-ray crystallography XDS – X-ray diffuse scattering XES – X-ray emission spectroscopy XPEEM – X-ray photoelectron emission microscopy XPS – X-ray photoelectron spectroscopy XRD – X-ray diffraction XRES – X-ray resonant exchange scattering XRF – X-ray fluorescence analysis XRR – X-ray reflectivity XRS – X-ray Raman scattering XRT – X-ray transmission XSW – X-ray standing wave technique
Sources: en.wikipedia.org
==== Australian plate ==== Lord Howe hotspot (22) 34°42′S 159°48′E, w= 0.8 az= 351° ±10° Tasmantid hotspot (39) 40°24′S 155°30′E, w= 0.8 az= 007° ±5° rate= 63 ±5 mm/yr East Australia hotspot (30) 40°48′S 146°00′E, w= 0.3 az= 000° ±15° rate= 65 ±3 mm/yr
== Economics == Since 2000, the therapeutic market for monoclonal antibodies has grown exponentially. In 2006, the "big 5" therapeutic antibodies on the market were bevacizumab, trastuzumab (both oncology), adalimumab, infliximab (both autoimmune and inflammatory disorders, 'AIID') and rituximab (oncology and AIID) accounted for 80% of revenues in 2006. In 2007, eight of the 20 best-selling biotechnology drugs in the U.S. are therapeutic monoclonal antibodies. This rapid growth in demand for monoclonal antibody production has been well accommodated by the industrialization of mAb manufacturing.
== Overview == Human growth hormone occurs naturally in the human body where it functions by stimulating growth of essentially all tissues, including bone. Use of exogenous human growth hormone (HGH), via injection, was originally for medical purposes until athletes began abusing HGH with the goal of increasing their abilities. Before recombinant human growth hormone (rHGH) was developed in 1981, HGH was only available by extracting it from the pituitary glands of cadavers. The arrival of rHGH combined with other peptide hormone advancements has increased the availability of HGH on both the legitimate and black markets. The first description of the use of GH as a doping agent was Dan Duchaine's "Underground Steroid handbook" which emerged from California in 1982; it is not known where and when GH was first used this way. In 1989 the International Olympic Committee became the first to brand human growth hormone a banned substance. Although abuse of human growth hormone for athletic purposes is illegal in the U.S., over the past decade it appears that abuse of HGH is present in all levels of sport. This is fueled at least in part by the fact that HGH is more difficult to detect than most other performance-enhancing drugs, such as anabolic steroids. This is because rHGH has an identical amino acid sequence to the native isoform of the hormone while GH from cadavers is indistinguishable from endogenous GH.
=== Exhibition in June 1933 in Paris === General Gouraud granted his patronage for an exhibition in the function hall of the town hall of the 13th district of Paris. The exhibition, Visions féeriques d’Orient (Fantasy Perspectives of the East), grouped together some 172 plates: 80 plates from the Basilique de Sainte-Sophie de Constantinople (Basilica of Hagia Sophia of Constantinople) and 92 plates from L'Art Islamique en Orient (Islamic Art in the East). Raymond’s name was not mentioned on the cover of the exhibition brochure.
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.